1. Australia Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
AusCann Group Holdings Ltd

AusCann Group Holdings Ltd

ACNNF
AusCann Group Holdings LtdUS flagOther OTC
0.00
USD
+0.00
- -
1.67MMarket Cap
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
0.88
0.04
- -
- -
- -
- -
-0.01
-0.03
-0.02
-0.02
-0.02
-0.06
- -
Free Cash Flow per Basic Share
0.08
- -
- -
- -
- -
- -
- -
- -
-0.02
-0.02
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-1.59
- -
- -
- -
- -
- -
0.01
0.04
0.13
0.11
0.12
0.04
0.04
Tangible Book Value per Share
-1.59
- -
- -
- -
- -
- -
0.01
0.05
0.14
0.11
0.08
0.04
0.04
Basic Weighted Avg Shares
8
271
395
410
410
514
1,536
272
308
317
352
441
441
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
-14,758.67
- -
-254,678.78
-13,281.18
-23,231.25
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
2
- -
Net Income, GAAP
7
12
- -
-1
- -
-1
-14
-8
-8
-7
-9
-26
-1
Effective Tax Rate (%)
- -
0.8
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
-14,249.65
- -
-220,855.59
-10,227.1
-88,642.28
- -
Working Capital
-13
1
1
1
- -
- -
14
13
34
23
15
7
13
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
-13
1
1
1
- -
- -
15
14
42
35
44
18
17
Return on Invested Capital (%)
- -
7,853.26
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-68,203.29
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
-31.55
-71.26
-61.92
-191.99
-194.68
-59.51
-29.2
-19.18
-22.44
-85.48
-5.96

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
462.09%
28.37%
-5.68%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
221.63%
24.67%
-96.03%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
-0.02
2022
- -
- -
- -
- -
-0.06
2023
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Christopher Mews B. Bus,
Full Time Employees
27
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
35 Havelock Street West Perth WA Australia 6005
IPO Date
Feb 10, 2017
Website
auscann.com.au
Similar Companies
PRF Technologies Ltd. (PRFX)
Curaleaf Holdings, Inc. (CURA.CN)
Mercury Biopharmaceutical Corporation (6932.TWO)
Elion Energy Company Limited (600277.SS)
Harvest Health & Recreation Inc. (HRVSF)
MJardin Group, Inc. (MJARF)
Business
AusCann Group Holdings Ltd (ASX:AC8) develops and commercializes cannabinoid-derived therapeutic products for human and animal health, focusing on standardized, pharmaceutical-grade formulations to address unmet medical needs in pain management and related indications. The company offers core products including Neuvis platform-based tetrahydrocannabinol and cannabidiol (THC/CBD) powder-filled hard-shell capsules for oral delivery with enhanced bioavailability; DermaCann topical formulations; MicroMax micronized cannabinoid products; and previously launched chronic pain treatments in 2.5:2.5mg and 10:10mg THC:CBD ratios, alongside veterinary medicines such as CPAT-01 liquid oral formulations through associated interests. It operates in the pharmaceuticals industry, primarily manufacturing and distributing medicinal cannabis products to healthcare professionals and veterinarians via rigorous good manufacturing practices, with geographic reach spanning Australia, New Zealand, Europe (including Germany via partnerships), Chile, and international markets. Founded in 2014 and headquartered in West Perth, Australia, the company holds licences for cultivation, production, and manufacture under Australia's Narcotic Drugs Act and pursues regulatory approvals globally. In recent developments, AusCann signed a binding term sheet in August 2025 to sell its core assets—including the Neuvis platform, 48% stake in CannPal Animal Therapeutics Ltd, and 19.99% interest in ECC Pharm—to Argent BioPharma Ltd (ASX:RGT) for US$15 million (A$23 million), with Argent securing an A$11 million funding facility in November 2025 from US funds to complete the transaction and support integration toward a US stock exchange listing. Earlier, in 2023, it expanded distribution agreements with European Cannabis Corporation Ltd to exclusively sell and distribute EU-GMP certified HAPA medicinal cannabis products in Australia and New Zealand, alongside a secured €1 million loan for HAPA Pharm BV's market launch in Germany; it also divested full ownership of CannPal in 2021 while retaining a 48% free-carried interest. These strategic moves follow delisting from the ASX in 2025 due to unpaid annual fees, shifting focus to asset monetization and partnerships amid operational wind-down.